Accretion Pharmaceuticals shareholders and shareholding pattern
NSE: ACCPLPharmaceuticals & Biotechnology
Accretion Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2025 · Issue price ₹101
Last close ₹181.00down ₹4.00 (2.16%)
Share price at the NSE close on 29 Oct 2026. Previous close ₹185.00.
29 Oct: open ₹181.00, high ₹181.00, low ₹181.00
52-week range of traded prices to 29 Oct 2026
₹54.60Low, 7 Nov 2025₹220.00High, 30 Sep 2026
- Next results date: the board meets on 31 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹201 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 20.81
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.68
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 27.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.23
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 3,600100.0% delivered
Accretion Pharmaceuticals' shareholding pattern for Sep 2026, filed on 17 Oct 2026, with every filing from Jun 2025: who owns its shares by group, its promoters by name and its public holders of 1% or more.
Who owns Accretion Pharmaceuticals, filing by filing
Per cent of the company's shares.
Sep 2026 filing
- Promoters73.52%
- Foreign institutions0.17%
- Indian institutions3.65%
- Individuals and others22.66%
Shareholding pattern, per cent
- Promoters
- Foreign institutions
- Indian institutions
- Individuals and others
| Per cent | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|
| 73.50% | 73.52% | 73.52% | 73.52% | 73.52% | 73.52% | |
| Indian promoters | 73.50% | 73.52% | 73.52% | 73.52% | 73.52% | 73.52% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. Public in the glossary | 26.50% | 26.48% | 26.48% | 26.48% | 26.48% | 26.48% |
| Shares in issue | 1,11,16,000 | 1,11,16,000 | 1,11,16,000 | 1,11,16,000 | 1,11,16,000 | 1,11,16,000 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. Shares locked in in the glossary | 82,75,600 | 81,70,000 | 81,70,000 | 81,70,000 | 22,23,200 | 22,23,200 |
| Promoters' shares locked in | 81,70,000 | 81,70,000 | 81,70,000 | 81,70,000 | 22,23,200 | 22,23,200 |
A dash is a line the filing did not state.
Accretion Pharmaceuticals promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is Vivek Ashok Kumar Patel, 17.69%. The filing names 46 more members with no shares.
| Holder | |||
|---|---|---|---|
| Vivek Ashok Kumar PatelIndividuals and Hindu undivided families | 17.69% | 19,66,500 | 28.26% |
| Hardik Mukundbhai PrajapatiIndividuals and Hindu undivided families | 17.69% | 19,66,500 | 28.26% |
| Harshad Nanubhai RathodIndividuals and Hindu undivided families | 17.69% | 19,66,500 | 28.26% |
| Mayur Popatlal SojitraIndividuals and Hindu undivided families | 17.69% | 19,66,500 | 28.26% |
| Shweta SojitraIndividuals and Hindu undivided families | 0.68% | 76,000 | 0.00% |
| Vaishaki Hardik PrajapatiIndividuals and Hindu undivided families | 0.68% | 76,000 | 0.00% |
| Ankita Vivek PatelIndividuals and Hindu undivided families | 0.68% | 76,000 | 0.00% |
| Pooja Harshad RathodIndividuals and Hindu undivided families | 0.68% | 76,000 | 0.00% |
| Rekhaben Karshandas GhetiyaIndividuals and Hindu undivided families | 0.02% | 2,400 | 0.00% |
No promoter shares are reported as pledged. Locked in is the share of the holder's own shares that cannot be sold yet, as after a listing or an allotment.
Largest public holders of Accretion Pharmaceuticals, filing by filing
Per cent, on the same shares as the split above.
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| UNICORN FUNDAlternative investment funds | – | – | 2.76% | 3.65% |
| RAJINDRA VALSALANResident individuals, over ₹2 lakh at face value | 1.13% | 1.04% | – | – |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. A dash is a filing that did not name the holder, which includes holding under one per cent.
Who moved in the Sep 2026 filing
Against the Jun 2026 filing. A filing names a public holder only at 1% or more, so a holder no longer named fell under 1% or sold out.
- Indian institutions: UNICORN FUND 3.65%, +0.89 pts